a Department of Surgery , The University of Hong Kong , Hong Kong SAR , China.
b Department of Medicine , The University of Hong Kong , Hong Kong SAR , China.
Int J Hyperthermia. 2017 Dec;33(8):882-887. doi: 10.1080/02656736.2017.1361047. Epub 2017 Aug 10.
Given that high-intensity focussed ultrasound (HIFU) of benign thyroid nodules often causes a massive release of thyroglobulin (Tg) into the circulation, we hypothesised a greater initial Tg rise may result in a greater nodule shrinkage 6 months after ablation.
One hundred and five patients who underwent HIFU for symptomatic benign thyroid nodule from 2015 to 2016 were analysed. Serum Tg and anti-Tg autoantibody were checked on treatment day (baseline) and 4 d after treatment. The % of Tg rise = [serum Tg on day-4 - baseline serum Tg]/[baseline serum Tg] * 100 while the nodule shrinkage as measured by volume reduction ratio (VRR) = [baseline volume - volume at 6-month]/[baseline volume] * 100. Treatment success was defined as VRR >50%.
At 6-month, the mean VRR was 62.2 ± 25.0% and 59 (76.6%) patients had treatment success. The mean baseline Tg level increased from 292.8 ± 672.7 ng/mL to 2022.7 ± 1759.8 ng/mL in the first-week. The % of Tg rise did not significantly correlate with either 3-month or 6-month VRR (p = 0.920 and p = 0.699, respectively). The mean % of Tg rise in the first week was not different between those with and without 6-month treatment success (368.2% vs. 1068.7%, p = 0.381). No clinical factors significantly correlated with treatment success.
There was an almost seven-fold increase in the mean Tg level 4 d after HIFU ablation. The % of Tg rise in the first week did not appear to correlate with the 6-month nodule shrinkage or treatment success.
高强度聚焦超声(HIFU)治疗良性甲状腺结节常导致大量甲状腺球蛋白(Tg)释放入血,我们假设初始 Tg 升高幅度较大可能导致消融后 6 个月结节体积缩小更多。
分析了 2015 年至 2016 年间 105 例因良性甲状腺结节症状而行 HIFU 治疗的患者。治疗当天(基线)和治疗后 4 天检测血清 Tg 和抗 Tg 自身抗体。Tg 升高率(%)=[治疗后第 4 天血清 Tg-基线血清 Tg]/[基线血清 Tg]×100,结节体积缩小率(VRR)=[基线体积-6 个月时体积]/[基线体积]×100。治疗成功定义为 VRR>50%。
6 个月时,平均 VRR 为 62.2±25.0%,59 例(76.6%)患者治疗成功。基线 Tg 水平从 292.8±672.7ng/mL 升高至治疗后第 1 周的 2022.7±1759.8ng/mL。Tg 升高率与 3 个月或 6 个月 VRR 均无显著相关性(p=0.920 和 p=0.699)。第 1 周 Tg 升高率均值在治疗成功和不成功患者之间无差异(368.2%比 1068.7%,p=0.381)。无临床因素与治疗成功显著相关。
HIFU 消融后第 4 天,平均 Tg 水平升高近 7 倍。第 1 周 Tg 升高率似乎与 6 个月结节缩小或治疗成功无关。